Similarly, non-cancer participants exhibited a progressive decrease in Klotho levels across PIV quartiles, with the most substantial reduction observed in Q4 (β = -67.82, 95% CI: -94.34, -41.29, P < 0.0001; P for trend < 0.0001). This evidence concerns the gene KL and cancer.